Levesam Oral Solution contains Levetiracetam 500 mg per 5 ml and is indicated as an adjunctive therapy for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam is an anticonvulsant agent that modulates synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure activity. This oral solution formulation allows for flexible dosing, particularly beneficial for pediatric and geriatric patients or those with swallowing difficulties. Levesam is rapidly absorbed with a favorable pharmacokinetic profile, exhibiting minimal protein binding and primarily renal excretion. The medication is generally well tolerated; common adverse effects may include somnolence, dizziness, headache, and fatigue. Dose adjustments may be necessary in patients with renal impairment. Levesam Oral Solution should be administered consistently with or without food and adherence to prescribed dosing schedules is essential to maintain therapeutic efficacy. It is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised when used concomitantly with other central nervous system depressants. Regular monitoring and consultation with a healthcare professional are recommended to optimize treatment outcomes.